Zealand Pharma and Helsinn Healthcare SA Announce Helsinn’s Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark and Lugano, Switzerland, 2013-05-28 11:16 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) and its partner, the Swiss pharmaceutical group Helsinn, a leading player in the cancer supportive care area, jointly announce that Helsinn has concluded a Phase IIa study with elsiglutide for the prevention of chemotherapy-induced diarrhea in cancer patients, with positive results. Elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) receptor agonist invented by Zealand and licensed to Helsinn for the development and use in cancer supportive care.
Help employers find you! Check out all the jobs and post your resume.
Copenhagen, Denmark and Lugano, Switzerland, 2013-05-28 11:16 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) and its partner, the Swiss pharmaceutical group Helsinn, a leading player in the cancer supportive care area, jointly announce that Helsinn has concluded a Phase IIa study with elsiglutide for the prevention of chemotherapy-induced diarrhea in cancer patients, with positive results. Elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) receptor agonist invented by Zealand and licensed to Helsinn for the development and use in cancer supportive care.
Help employers find you! Check out all the jobs and post your resume.